Tsutomu Nakagawa
Director/Board Member at SUMITOMO PHARMA CO., LTD.
Network origin in Tsutomu Nakagawa first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 39 | |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA.
14
| Subsidiary | Pharmaceuticals: Major | 14 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Tsutomu Nakagawa via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BEMIS COMPANY, INC. | Containers/Packaging | Director/Board Member | |
| RESONA HOLDINGS, INC. | Regional Banks | Director/Board Member | |
Resona Bank Ltd.
 Resona Bank Ltd. Regional BanksFinance Resona Bank, Ltd. provides commercial banking services. It operates through the following segments: Personal, Corporate, and Market. The Personal segment handles financial services for individual customers including personal loans, asset management, and inherited asset consulting. The Corporate segment focuses on lending, asset management that uses trusts, real estate operations, enterprise pensions, and business growth support. The Market segment engages in funds, foreign and local exchanges, bonds, and derivatives. It also offers current and savings accounts, mortgages, debit and credit cards, pension and insurance products, online and phone banking, and investment trusts. The company was founded on May 15, 1918 and is headquartered in Osaka, Japan. | Regional Banks | Director/Board Member | |
| GURUNAVI, INC. | Internet Software/Services | Director/Board Member | |
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Tolero Pharmaceuticals, Inc.
 Tolero Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Tolero Pharmaceuticals, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage biopharmaceutical company with a single-minded purpose to alleviate human suffering through the development of medicines to treat cancer and other serious human diseases. The company is headquartered in Lehi, UT. | Pharmaceuticals: Other | Director/Board Member | |
| ROIVANT SCIENCES LTD. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal | |
| SUMITOMO CHEMICAL CO., LTD. | Chemicals: Specialty | Corporate Officer/Principal Corporate Officer/Principal | |
| LIXIL CORPORATION | Building Products | Director/Board Member | |
| IHI CORPORATION | Industrial Machinery | Director/Board Member | |
| JCR PHARMACEUTICALS CO., LTD. | Pharmaceuticals: Major | President Director/Board Member | |
| BANK OF JAPAN | General Government | Director/Board Member | |
| SEIKO EPSON CORPORATION | Computer Peripherals | Chairman | |
Kyoto Pharmaceutical Industries Ltd.
 Kyoto Pharmaceutical Industries Ltd. Pharmaceuticals: MajorHealth Technology Kyoto Pharmaceutical Industries Ltd. engages in pharmaceutical products manufacturing. Its products include pharmaceuticals to regulate high-blood pressure, Ischemic heart disease treatment, digitalis formulation, and constipation remedies. The firm also develops and produces laxatives, anti-flatulence and anti-diarrheal medicines, and decongestants and cold medicines. The company was founded on September 5, 1946 and is headquartered in Kyoto, Japan. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
FUJIFILM Toyama Chemical Co. Ltd.
 FUJIFILM Toyama Chemical Co. Ltd. Pharmaceuticals: OtherHealth Technology Part of FUJIFILM Holdings Corp., FUJIFILM Toyama Chemical Co. Ltd. brings innovative solutions to various industries such as healthcare, graphic systems, and digital imaging. The company is based in Tokyo, Japan. The Japanese company's core technologies include chemical, mechanical, optical, electronic, and imaging technologies. With revenues of $21 billion in 2020, the company is committed to responsible environmental stewardship and good corporate citizenship. The company was founded in 1968, and the CEO is Misao Tsuda. FUJIFILM Toyama Chemical Co. was acquired by FUJIFILM Holdings Corp. from Daiichi Sankyo Co., Ltd. on October 01, 2006. | Pharmaceuticals: Other | Director/Board Member | |
| Boston College | College/University | Doctorate Degree | |
| MUTUAL CORPORATION | Industrial Machinery | Director/Board Member | |
| KOEI CHEMICAL COMPANY, LIMITED | Chemicals: Major Diversified | Comptroller/Controller/Auditor | |
| University of Tokyo | College/University | Graduate Degree Undergraduate Degree | |
| University of Science & Technology of China | College/University | Undergraduate Degree | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member | |
| Hiroshima University | College/University | Doctorate Degree | |
The Committee of 200
 The Committee of 200 Miscellaneous Commercial ServicesCommercial Services The Committee of 200 operates as a membership organization for women entrepreneurs and corporate innovators. | Miscellaneous Commercial Services | Director/Board Member | |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Pharmaceuticals: Major | President | |
UCB Research, Inc.
 UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| Daiamed LLC | Chief Tech/Sci/R&D Officer | ||
Nihon Medi-Physics Co., Ltd.
 Nihon Medi-Physics Co., Ltd. Pharmaceuticals: MajorHealth Technology Nihon Medi-Physics Co., Ltd. is a leading manufacturer of radiopharmaceuticals, based in Japan. The Japanese company is engaged in ensuring stable supply and research and development of new products. It is also working on research and development of "theranostics," a novel medical technology to provide optimal medical service to each patient, as well as on the dissemination of nuclear medicine in Asian countries by licensing its products. Nihon Medi-Physics Co. was founded in 1973, and the CEO is Nobuhiko Tamura. | Pharmaceuticals: Major | Chief Executive Officer | |
| National Police Agency | General Government | Director/Board Member | |
| Financial Services Agency | General Government | Corporate Officer/Principal | |
| Beijing Pharmasciences Co. Ltd. | Chief Executive Officer | ||
Sumitomo Pharma Animal Health Co., Ltd.
 Sumitomo Pharma Animal Health Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Pharma Animal Health Co., Ltd. is a Japanese company that manufactures and supplies pharmaceuticals, food ingredients, food additives, veterinary medicines, and diagnostics. The company is based in Osaka, Japan and was founded in 2010. | Pharmaceuticals: Major | Chief Executive Officer | |
Primetals Technologies Ltd.
 Primetals Technologies Ltd. Information Technology ServicesTechnology Services Primetals Technologies Ltd. operates as a engineering and plant construction company. It manures of steel and iron products. The company was founded in January 2015 and is headquartered in London, the United Kingdom. | Information Technology Services | Director of Finance/CFO | |
Sunovion Pharmaceuticals Europe Ltd.
 Sunovion Pharmaceuticals Europe Ltd. Pharmaceuticals: MajorHealth Technology Sunovion Pharmaceuticals Europe Ltd. is a British European pharmaceutical company founded in 2013 that is dedicated to improving the lives of patients through the supply of essential medicines. The company is based in London, UK. The company commercializes and distributes a portfolio of specialty brands and hospital products in 40 countries worldwide, both directly and through strategic partnerships. The company's vision is to become a recognized partner of choice through their commercial excellence, patient focus, and presence across the globe. Sunovion Pharmaceuticals Europe aims to have a positive impact on society through their pioneering focus on their environment, social, and governance (ESG) goals. | Pharmaceuticals: Major | Chief Executive Officer | |
Meltin MMI KK
 Meltin MMI KK Medical SpecialtiesHealth Technology Meltin MMI KK develops bio-signal interface technologies. It offers biosignal processing and cable-driven ststems. The company was founded by Sumio Ito, Masahoro Kasuya and Tatsuya Seki and is headquartered in Tokyo, Japan. | Medical Specialties | Director/Board Member | |
| MYOVANT SCIENCES LTD. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
1843 Capital LLC
 1843 Capital LLC Investment ManagersFinance 1843 Capital LLC (1843 Capital) is a venture capital firm founded in 2016 by Tracy Killoren Chadwell. The firm is headquartered in Greenwich, Connecticut. | Investment Managers | Consultant / Advisor | |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Director/Board Member | |
| UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member | |
Altavant Sciences, Inc.
 Altavant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC. | Pharmaceuticals: Major | Director/Board Member | |
| Pancreas Research Foundation of Japan | Chairman | ||
Sumitovant Biopharma, Inc.
 Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Director/Board Member Director/Board Member |
Statistics
International
| Japan | 26 |
| United States | 18 |
| United Kingdom | 6 |
| China | 3 |
| Bermuda | 2 |
Sectoral
| Health Technology | 22 |
| Finance | 6 |
| Consumer Services | 5 |
| Process Industries | 4 |
| Commercial Services | 4 |
Operational
| Director/Board Member | 95 |
| Corporate Officer/Principal | 54 |
| Independent Dir/Board Member | 25 |
| President | 13 |
| Chief Executive Officer | 12 |
Most connected contacts
| Insiders | |
|---|---|
| Adele Gulfo | 16 |
| Nobuhiro Endo | 11 |
| Roger Xie | 10 |
| Shigeyuki Nishinaka | 9 |
| Hiroshi Nomura | 8 |
| Masayo Tada | 8 |
| Jack Britts | 7 |
| Hiroshi Sato | 6 |
| Junsuke Fujii | 6 |
| Hidehiko Sato | 6 |
| Toshihiko Hibino | 5 |
| Nobuhiko Tamura | 5 |
| Saburo Hamanaka | 4 |
| Koji Ishida | 4 |
| Toru Kimura | 3 |
- Stock Market
- Insiders
- Tsutomu Nakagawa
- Company connections
